PacBio appoints former Moderna CFO David Meline to board of directors

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

David Meline appointed as Class II director effective October 13, 2023, term expiring at 2024 annual meeting.
Meline most recently served as CFO of Moderna; previously CFO of Amgen and 3M, with 20+ years at GM.
He also serves on boards of ABB Ltd. and will join HP Inc. board on November 1, 2023.
Meline will participate in standard non-employee director compensation policy and indemnification agreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Meline

Class II Director

PACB · PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Effective: 2023-10-13
Filed: October 16, 2023, 7:59 PM ET

On October 13, 2023, the Board (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) increased the size of the Board to ten directors and, upon the recommendation of its Corporate Governance and Nominating Committee, appointed David Meline to serve as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Meline was appointed as Class II Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

Action: appointed
Role: Class II Director

Exact text from the filing

On October 13, 2023, the Board (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) increased the size of the Board to ten directors and, upon the recommendation of its Corporate Governance and Nominating Committee, appointed David Meline to serve as a Class II director

View on SEC.gov

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001299130-23-000122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.